Skip to content

Research on key technologies for standardized diagnosis and treatment of alveolar cleft

Research on key technologies for standardized diagnosis and treatment of alveolar cleft

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073058
Enrollment
Unknown
Registered
2023-06-30
Start date
2023-06-30
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar cleft

Interventions

6-8 years old bone grafting group:Equal amounts of autologous iliac bone grafting in patients aged 6-8 years
9-11 years old bone grafting group:Equal amounts of autologous iliac bone grafting in patients aged 9-11 years
Group 1:Extract 10ml of bone marrow blood per 1cm3, centrifuge at 2000rpm for 15 minutes to extract nucleated cells and transplant with ß-TCP to repair alveolar crista cleft defect
Group 2:Extract 20ml of bone marrow blood per 1cm3, centrifuge at 2000rpm for 15 minutes, and then centrifuge the nucleated cells twice (centrifuge at 1000rpm for 5 minutes) to extract nucleated cells

Sponsors

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 25 Years

Inclusion criteria

Inclusion criteria: Part1:1.6-11 years old; 2. Children with unilateral third-degree cleft lip or cleft lip and palate diagnosed at birth, who have previously undergone cleft lip repair surgery; 3. Obvious alveolar ridge fissures in preoperative diagnosis; 4. Alveolar cleft repair and gingival periotoplasty (GPP) have not been performed before this alveolar cleft repair; 5. No orthodontic treatment has been performed before this alveolar cleft repair surgery; 6. Normal communication ability; 7. The admission examination is basically normal; 8. The patient's guardian agrees to participate in this experiment and signs the informed consent form; 9. Not participating in other clinical trials at the same time; 10. Patients who meet the above conditions within 24 months of the start of the project. Part 2:(1) congenital unilateral cleft lip and palate alveolar cleft; (2) The condition is stable for more than 1 year; (3) All preoperative examinations are normal; (4) 8-25 years old; (5) Gender is not limited; (6) Those who agree to sign the informed consent form of the experiment; (7) At the same time, it did not participate in other clinical trials.

Exclusion criteria

Exclusion criteria: Part1:1. Combined with giant palatal fistula; 2. Patients with abnormal results of various routine examinations on admission; 3. Patients with a history of other bone metabolic diseases that may affect bone healing or related examination findings (such as osteoporosis, osteomalacia, etc.); 4. Active period of infectious diseases; 5. Patients with poor systemic nutritional status; 6. In addition to cleft lip and palate, there are other craniofacial deformities; 7. Those who are participating in other clinical trials and have not reached the end point; 8. Patients with allergies or allergies to materials, reagents and drugs related to disease treatment (ß-TCP, titanium nails). Part2:(1) Patients with abnormal results of various routine examinations on admission; (2) Those who need preoperative orthodontic treatment, or have the intention of orthodontic treatment within 1 year after surgery; (3) Syndromic alveolar crest (such as forebrain fissure, etc.); (4) Patients with palatal fistula or who have undergone tongue flap treatment; (5) Patients with teeth in the bone grafting area who need to be extracted may affect postoperative osteogenesis; (6) After radiotherapy or multiple surgeries or trauma, there is extensive scarring in the affected area and poor blood supply; (7) Patients who have recently received BMP growth factor and other bone growth-promoting factors; (8) Patients with local foci of infection in the whole body or surgical area; (9) Patients with allergies or allergies to materials, reagents and drugs related to disease treatment (ß-TCP, titanium nails); (10) Those who are participating in other clinical trials and have not reached the endpoint.

Design outcomes

Primary

MeasureTime frame
Osteogenesis rate;Bone graft volume;Osteogenic volume;

Secondary

MeasureTime frame
Craniofacial Bone Defect Repair Score;

Countries

China

Contacts

Public ContactWang Yongqian

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

surgeonfrank@163.com+86 10 8877 1983

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026